TGTX
TG Therapeutics Surpasses Revenue Guidance and Delivers Strong Q4 Results Amid Exciting Business Milestones
TG Therapeutics, a biotechnology company focused on developing and commercializing innovative therapies for diverse patient populations, has reported outstanding fourth-quarter (Q4) and full-year 2024 financial results, exceeding its targeted revenue guidance. The company's full-year 2024 U.S. revenues of $310 million significantly outperformed its initial projections, demonstrating the